但是，他将其和一种名为艾比特思的抗体联合了起来，后者通过与促进癌细胞扩散和生长的蛋白结合来对它进行抑制。
He did, however, combine it with Erbitux, an antibody that binds to and thus disables a protein that promotes the proliferation and growth of cells.
接受艾比特思和化学疗法联合治疗的222名患者平均幸存了40周。
The 222 patients treated with Erbitux and chemotherapy survived for an average of 40 weeks.
例如，艾比特思和名为表皮生长因子受体(EGFR)的细胞表面蛋白的结合。
Erbitux, for example, binds to a cell-surface protein called epidermal growth-factor receptor (EGFR).
例如，艾比特思和名为表皮生长因子受体(EGFR)的细胞表面蛋白的结合。
Erbitux, for example, binds to a cell-surface protein called epidermal growth-factor receptor (EGFR).
应用推荐